- BioNxt Solutions (BNXTF, Financial) expects to meet the June 30, 2025, deadline for filing its 2024 annual financial statements.
- Audit materials for the company's German subsidiaries are complete, and draft financials are prepared.
- The Management Cease Trade Order (MCTO) does not affect regular shareholders' ability to trade.
BioNxt Solutions Inc. (BNXTF) has issued a bi-weekly update regarding its Management Cease Trade Order (MCTO), which was implemented by the British Columbia Securities Commission on May 1, 2025. The MCTO restricts the CEO and CFO from trading company securities until BioNxt files its annual financial documents for the year ending December 31, 2024. The deadline for filing these documents is June 30, 2025.
The company has announced that audit materials for its German subsidiaries have been completed and that draft financials have been prepared and submitted to its audit firm. BioNxt remains committed to meeting the filing deadline and has confirmed that there have been no material changes to its business or operations since the initial default announcement.
Importantly, the MCTO does not extend to regular shareholders, who can continue to trade BioNxt stock without restriction. BioNxt will maintain transparency by providing bi-weekly status updates until the filing requirement is satisfied and the MCTO is lifted. Investors are advised to keep an eye on forthcoming updates as the company works towards resolving the situation.
